Compare · MRNA vs REPL
MRNA vs REPL
Side-by-side comparison of Moderna Inc. (MRNA) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and REPL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 42.6x REPL ($1.49B).
- REPL has been more active in the news (22 items in the past 4 weeks vs 10 for MRNA).
- Both have 25 recent analyst ratings on file.
- Company
- Moderna Inc.
- Replimune Group Inc.
- Price
- $158.81+14.40%
- $15.80+7.56%
- Market cap
- $63.41B
- $1.49B
- 1M return
- -
- +82.98%
- 1Y return
- -
- +178.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 10
- 22
- Recent ratings
- 25
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest MRNA
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Latest REPL
- Director Astley-Sparke Philip gifted 50,000 shares, decreasing direct ownership by 4% to 1,362,414 units (SEC Form 4)
- Chief Financial Officer Hill Emily Luisa sold $132,176 worth of shares (9,256 units at $14.28), decreasing direct ownership by 4% to 215,852 units (SEC Form 4) to satisfy withholding tax
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-3ASR filed by Replimune Group Inc.
- Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
- Chief Executive Officer Patel Sushil sold $510,253 worth of shares (39,341 units at $12.97), decreasing direct ownership by 5% to 708,151 units (SEC Form 4) to cover taxes
- Chief Financial Officer Hill Emily Luisa sold $148,481 worth of shares (11,448 units at $12.97), decreasing direct ownership by 5% to 225,108 units (SEC Form 4) (for tax liability)
- Chief Medical Officer Xynos Konstantinos sold $148,468 worth of shares (11,447 units at $12.97), decreasing direct ownership by 5% to 224,215 units (SEC Form 4) (tax liability)
- Chief Accounting Officer Schwendenman Andrew sold $98,987 worth of shares (7,632 units at $12.97), decreasing direct ownership by 7% to 99,425 units (SEC Form 4) (withholding tax)